ABG V-SIV IX Ltd - 03 Feb 2026 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
10%+ Owner
Signature
ABG V-SIV IX Limited, By: Ally Bridge Group Global Life Science Capital Partners V, L.P., By: ABG Global Life Science Capital Partners V GP, L.P., By: ABG Global Life Science Capital Partners V GP Limited, By: /s/ Fan Yu
Issuer symbol
PMN
Transactions as of
03 Feb 2026
Net transactions value
$0
Form type
3
Filing time
25 Feb 2026, 19:30:29 UTC
SEC
View on sec.gov

Reporting Owners (5)

Name Relationship Address Signature Signature date CIK
ABG V-SIV IX Ltd 10%+ Owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK ABG V-SIV IX Limited, By: Ally Bridge Group Global Life Science Capital Partners V, L.P., By: ABG Global Life Science Capital Partners V GP, L.P., By: ABG Global Life Science Capital Partners V GP Limited, By: /s/ Fan Yu 25 Feb 2026 0002113290
Ally Bridge Group Global Life Science Capital Partners V, L.P. 10%+ Owner C/O MAPLES CORPORATE SERVICES LIMITED, P.O. BOX 309, UGLAND HOUSE,, GRAND CAYMAN,, CAYMAN ISLANDS Ally Bridge Group Global Life Science Capital Partners V, L.P., By: ABG Global Life Science Capital Partners V GP, L.P., its GP, By: ABG Global Life Science Capital Partners V GP Limited, its GP, By: /s/ Fan Yu, Director 25 Feb 2026 0001951727
ABG Global Life Science Capital Partners V GP, L.P. 10%+ Owner C/O MAPLES CORPORATE SERVICES LIMITED, P.O. BOX 309, UGLAND HOUSE,, GRAND CAYMAN,, CAYMAN ISLANDS ABG Global Life Science Capital Partners V GP, L.P., By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu, Director 25 Feb 2026 0002080886
ABG Global Life Science Capital Partners V GP Ltd 10%+ Owner C/O MAPLES CORPORATE SERVICES LIMITED, P.O. BOX 309, UGLAND HOUSE,, GRAND CAYMAN,, CAYMAN ISLANDS ABG Global Life Science Capital Partners V GP Limited, By: /s/ Fan Yu, Director 25 Feb 2026 0002080887
ABG V-SIV X Ltd 10%+ Owner C/O MAPLES CORPORATE SERVICES LIMITED, P.O. BOX 309, UGLAND HOUSE,, GRAND CAYMAN,, CAYMAN ISLANDS ABG V-SIV X Limited, By: /s/ Fan Yu, Director 25 Feb 2026 0002113291

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMN Common Shares 943,090 03 Feb 2026 See Footnote F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMN Warrants 03 Feb 2026 Common Shares 700,741 $14.40 See Footnote F2, F3, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.
F2 Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
F3 Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
F4 Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
F5 The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.
F6 The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

Remarks:

Following the filing of this Form 3, the Reporting Persons are expected to file Forms 4 jointly with ABG Management Ltd., Ally Bridge MedAlpha Master Fund L.P., Ally Bridge Group (NY) LLC, Fan Yu and Slanix Alex.